Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare CURE vs. LNYN

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Lanyon Investment Fund Active ETF (LNYN). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

LNYN

Popularity

Low

Low

Pearlers invested

82

1

Median incremental investment

$674.92

$543.50

Median investment frequency

Monthly

Quarterly

Median total investment

$2,318.70

$571.35

Average age group

> 35

26 - 35

Key Summary

CURE

LNYN

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 46.59m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

LNYN.AX was created on 2019-09-02 by Lanyon. The fund's investment portfolio concentrates primarily on total market equity. The Funds investment return objective is to earn returns superior to the combined benchmark consisting of 75% of the S&P/ASX 300 Accumulation Index and 25% of the MSCI All Country World Index net total returns AUD index after taking account of fees and costs incurred by the Fund.

Top 3 holdings

Moderna Inc (2.72 %)

Exelixis Inc (1.80 %)

Amgen Inc (1.79 %)

Mineral Resources Ltd (16.79 %)

Telstra Group Ltd (14.42 %)

Newmont Corp Chess Depository Interest (12.48 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (96.74 %)

Switzerland (1.43 %)

United Kingdom of Great Britain and Northern Ireland (1.23 %)

Australia (56.95 %)

United States (18.38 %)

United Kingdom of Great Britain and Northern Ireland (15.27 %)

Management fee

0.45 %

0 %

Key Summary

CURE

LNYN

Issuer

Global X

Lanyon

Tracking index

S&P Biotechnology Select Industry

75% S&P/ASX 300 Accumulation Index - AUD - Benchmark TR Net - 25% MSCI All Country World Index in AUD - AUD - Benchmark TR Net - NET_RETURN

Asset class

ETF

ETF

Management fee

0.45 %

0 %

Price

$77.21

$1.95

Size

$50.133 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

0.03 %

1.97 %

Market

ASX

ASX

First listed date

12/11/2018

31/07/2024

Purchase fee

$6.50

$6.50

Community Stats

CURE

LNYN

Popularity

Low

Low

Pearlers invested

82

1

Median incremental investment

$674.92

$543.50

Median investment frequency

Monthly

Quarterly

Median total investment

$2,318.70

$571.35

Average age group

> 35

26 - 35

Pros and Cons

CURE

LNYN

Pros

  • Higher exposure to US market

  • Higher price growth

  • Higher exposure to AU market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to AU market

  • Higher management fee

  • Lower distribution yield

  • Lower exposure to US market

  • Lower price growth

CURE

LNYN

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield